Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials
详细信息 查看全文
- 作者：Salvatore Galdy ; salvatore.galdy@ieo.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Chiara Alessandra CellaAuthor Vitae ; Francesca SpadaAuthor Vitae ; Sabina MurgioniAuthor Vitae ; Anna Maria FrezzaAuthor Vitae ; Simona Paola RavendaAuthor Vitae ; Maria Giulia ZampinoAuthor Vitae ; Nicola FazioAuthor Vitae
- 关键词：Advanced gastric cancer ; Second-line chemotherapy ; Molecular targeted agents ; Randomized controlled trials
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：1-12
- 全文大小：1319 K
文摘
- •
Progressive gastric cancer patients may benefit from a second-line therapy.
- •
Monochemotherapy (both irinotecan and taxanes) is superior to BSC.
- •
Novel targeted agents such as ramucirumab and apatinib are really promising.
- •
Ramucirumab is the first targeted drug approved by FDA and EMA in second-line.
- •
Future investigation should provide stronger predictive markers to targeted therapy.